Healthequity Price to Earnings Ratio Trend from 2010 to 2022

HQY
 Stock
  

USD 66.75  0.06  0.09%   

Healthequity Price to Earnings Ratio yearly trend continues to be fairly stable with very little volatility. Price to Earnings Ratio will likely drop to -103.48 in 2022. During the period from 2010 to 2022, Healthequity Price to Earnings Ratio regression line of anual values had r-squared of 0.01278 and arithmetic mean of  89.48. Healthequity Direct Expenses is fairly stable at the moment as compared to the past year. Healthequity reported Direct Expenses of 332.85 Million in 2021. Cost of Revenue is likely to rise to about 359.1 M in 2022, whereas Consolidated Income is likely to drop (45.5 M) in 2022.
  
Refresh
Check Healthequity financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Healthequity main balance sheet or income statement drivers, such as Direct Expenses of 359.1 M, Cost of Revenue of 359.1 M or Gross Profit of 457.2 M, as well as many exotic indicators such as Interest Coverage of 1.19, Long Term Debt to Equity of 0.71 or PPandE Turnover of 35.09. Healthequity financial statements analysis is a perfect complement when working with Healthequity Valuation or Volatility modules. It can also supplement various Healthequity Technical models. Please check the analysis of Healthequity Correlation against competitors.

Healthequity Quarterly Price to Earnings Ratio

(94.424)

Share

Healthequity Price to Earnings Ratio Breakdown

Showing smoothed Price to Earnings Ratio of Healthequity with missing and latest data points interpolated. An alternative to [PE] representing the ratio between [Price] and [EPSUSD].Healthequity's Price to Earnings Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Healthequity's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 789.30 X10 Years Trend
Increasing
Very volatile
 Price to Earnings Ratio 
Share
      Timeline 

Healthequity Price to Earnings Ratio Regression Statistics

Arithmetic Mean 89.48
Geometric Mean 82.99
Coefficient Of Variation 216.68
Mean Deviation 98.85
Median 53.26
Standard Deviation 193.90
Sample Variance 37,596
Range 799.73
R-Value 0.11
Mean Square Error 40,489
R-Squared 0.01278
Significance 0.71
Slope 5.63
Total Sum of Squares 451,150

Healthequity Price to Earnings Ratio History

2015 74.31
2016 102.78
2017 64.08
2018 51.95
2019 111.97
2020 696.25
2021 -100.83
2022 -103.48

About Healthequity Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Healthequity income statement, its balance sheet, and the statement of cash flows. Healthequity investors use historical funamental indicators, such as Healthequity's Price to Earnings Ratio, to determine how well the company is positioned to perform in the future. Although Healthequity investors may use each financial statement separately, they are all related. The changes in Healthequity's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Healthequity's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Healthequity Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Healthequity. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Price to Earnings Ratio(100.83) (103.48) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA107 M95.1 M
Earnings before Tax-66.7 M-68.5 M
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company was incorporated in 2002 and is headquartered in Draper, Utah. Healthequity operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 3688 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Healthequity without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Healthequity using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of Healthequity Correlation against competitors. Note that the Healthequity information on this page should be used as a complementary analysis to other Healthequity's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Healthequity Stock analysis

When running Healthequity price analysis, check to measure Healthequity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Healthequity is operating at the current time. Most of Healthequity's value examination focuses on studying past and present price action to predict the probability of Healthequity's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Healthequity's price. Additionally, you may evaluate how the addition of Healthequity to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Is Healthequity's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Healthequity. If investors know Healthequity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Healthequity listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.96
Market Capitalization
5.6 B
Quarterly Revenue Growth YOY
0.12
Return On Assets
0.0059
Return On Equity
-0.0299
The market value of Healthequity is measured differently than its book value, which is the value of Healthequity that is recorded on the company's balance sheet. Investors also form their own opinion of Healthequity's value that differs from its market value or its book value, called intrinsic value, which is Healthequity's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Healthequity's market value can be influenced by many factors that don't directly affect Healthequity's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Healthequity's value and its price as these two are different measures arrived at by different means. Investors typically determine Healthequity value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Healthequity's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.